Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852513 · ClinicalTrials.gov registry record · Phase 4
Allergic Rhinitis Changes the Sinus Microbiome
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
NCT01852513 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 39 participants.
The verdict
NCT01852513, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
Study Summary
The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.
Interventions
- DRUG Placebo nasal spray
- DRUG QNASL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852513
The ClinicalTrials.gov registry entry for NCT01852513 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT01852513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852513 about?
NCT01852513 is a clinical study titled "Allergic Rhinitis Changes the Sinus Microbiome". The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.
What is the current status of trial NCT01852513?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01852513?
The interventions under investigation include: Placebo nasal spray (DRUG), QNASL (DRUG).
Who is sponsoring clinical trial NCT01852513?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.